Orthocell announces research collaboration

Company News

by Jessica Amir

Orthocell Limited (ASX:OCC) has entered into a research collaboration with Johnson and Johnson for its stem cell products.

The product, Ortho-ATI, is a non-surgical approach that treats resistant tendons and ligament injuries.

The companies will conduct a collaborative study in the first quarter of 2017 and conduct a trial with leading orthopaedic surgeons.

Ortho-ATI is available in Australian and New Zealand.

Orthocell posted a net loss $3.8 million at 30 June 2016.

Jessica Amir

Finance News Network
Jessica presents the Market Outlook and company news. She joined FNN in January 2017. She has been in broadcast journalism for over five years. She has worked as a journalist with Sky News Business, ABC 1 and ABC24. She has also worked in regional Australia for Prime 7 and WIN News. She is also a qualified financial planner and a Masters of Applied Finance student.